Effect of Olmesartan on Endothelial Dysfunction After Everolimus Eluting Stent Implantation

Effect of Olmesartan on Endothelial Dysfunction After Everolimus Eluting Stent Implantation - Effect of Olmesartan on Endothelial Dysfunction After Everolimus Eluting Stent Implantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007728

Enrollment

Registered

2012-04-11

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension and coronary artery disease

Interventions

Olmesartan group Olmesartan is administered up to 40mg/day. If not effective, calcium channel blocker, beta blocker, diuretic, alpha blocker will be added. Non olmesartan group Amlodipine is admin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hypertensive patients planned to implant drug eluting stent. 2. Patients who are admitted to our hospital.

Exclusion criteria

Exclusion criteria: 1. Recent myocardial infarction (within the previous 48 hours). 2. An ejection fraction of less than 40%. 3. An unprotected left main coronary artery disease. 4. A history of coronary artery vasospasm. 5. Severe calcified or adherence of thrombus in target vessel. 6. Bilateral renal artery stenosis or unilateral renal artery stenosis of remnant kidney. 7. Hyperkalemia (serum kalium>5.0mEq/L). 8. Renal insufficiency (serum creatinnin > 3.0 mg/dL). 9. Liver function disorder (AST or ALT > 100 U/L). 10. Expectant mother. 11. Inappropriate patients judged by the physician in charge.

Design outcomes

Primary

Measure	Time frame
endothelial function	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026